Corcept Therapeutics Inc (NASDAQ: CORT) is 47.97% higher on its value in year-to-date trading and has touched a low of $20.84 and a high of $50.07 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CORT stock was last observed hovering at around $48.92 in the last trading session, with the day’s loss setting it -0.86%.
Currently trading at $48.06, the stock is 3.80% and 18.66% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.79 million and changing -1.76% at the moment leaves the stock 57.39% off its SMA200. CORT registered 76.37% gain for a year compared to 6-month gain of 113.79%. The firm has a 50-day simple moving average (SMA 50) of $40.5028 and a 200-day simple moving average (SMA200) of $30.53515.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 9.23% loss in the last 1 month and extending the period to 3 months gives it a 37.83%, and is 1.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.51% over the week and 3.88% over the month.
Corcept Therapeutics Inc (CORT) has around 352 employees, a market worth around $5.02B and $569.61M in sales. Current P/E ratio is 42.63 and Fwd P/E is 25.74. Profit margin for the company is 21.94%. Distance from 52-week low is 130.61% and -4.01% from its 52-week high. The company has generated returns on investments over the last 12 months (20.76%).
Corcept Therapeutics Inc quarterly earnings per share for the current quarter are estimated at 0.28 with sales reaching $171.97M over the same period.The EPS is expected to grow by 19.28% this year, but quarterly earnings will post 37.00% year-over-year. Quarterly sales are estimated to grow 43.70% in year-over-year returns.
397.0 institutions hold shares in Corcept Therapeutics Inc (CORT), with institutional investors hold 98.31% of the company’s shares. The shares outstanding are 103.41M, and float is at 89.95M with Short Float at 23.92%. Institutions hold 86.96% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 16.54 million shares valued at $537.36 million. The investor’s holdings represent 16.0901 of the CORT Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 9.55 million shares valued at $310.4 million to account for 9.2943 of the shares outstanding. The other top investors are INGALLS & SNYDER LLC which holds 8.24 million shares representing 8.0144 and valued at over $267.66 million, while RENAISSANCE TECHNOLOGIES LLC holds 6.7249 of the shares totaling 6.91 million with a market value of $224.59 million.
Corcept Therapeutics Inc (CORT) Insider Activity
The most recent transaction is an insider sale by Guyer William, the company’s Chief Development Officer. SEC filings show that Guyer William sold 10,000 shares of the company’s common stock on Oct 01 ’24 at a price of $46.28 per share for a total of $0.46 million. Following the sale, the insider now owns 5796.0 shares.
Corcept Therapeutics Inc disclosed in a document filed with the SEC on Oct 01 ’24 that Robb Gary Charles (Chief Business Officer) sold a total of 11,000 shares of the company’s common stock. The trade occurred on Oct 01 ’24 and was made at $46.28 per share for $0.51 million. Following the transaction, the insider now directly holds 22772.0 shares of the CORT stock.
Still, SEC filings show that on Oct 01 ’24, Robb Gary Charles (Officer) Proposed Sale 11,000 shares at an average price of $46.28 for $0.51 million. The insider now directly holds shares of Corcept Therapeutics Inc (CORT).
